Compare Natera Inc. Common Stock (NTRA) vs Okta, Inc. (OKTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Okta, Inc. — how do they compare? Natera Inc. Common Stock trades at $392.66 (market cap $57.03B), while Okta, Inc. trades at $202.2 (market cap $37.05B). The key difference: Natera Inc. Common Stock is the larger of the two by market cap, and Okta, Inc. is more actively traded (4,638,855 versus 1,131,157). Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Okta, Inc. for 44 Days on average.
| NTRA | OKTA | |
|---|---|---|
Market Cap | $57.03B | $37.05B |
Volume | 1,131,157 | 4,638,855 |
Sector | Health | Technology |
52-Week High | $425.64 | $232.13 |
52-Week Low | $179.42 | $62.93 |
Typical Hold Time | 0 Days | 44 Days |
Enterprise Value | $56.18B | $34.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
OKTA trades at $226.53, down 0.24% on the day, with a bullish technical outlook supported by moving averages and strong analyst sentiment. The company reported three consecutive quarterly earnings beats, with Q3 2026 results pending. Revenue growth is robust, rising to $2.61B in 2025, while profitability improved significantly to a net income margin of 9.63% in 2026. Recent news highlights AI security initiatives, including the AI Agent Security Blueprint Alliance unveiled at Oktane 2026.
Outlook remains positive due to earnings momentum and AI positioning, but risks include high valuation multiples and competitive pressures. The consensus price target is $201.76, below the current price, suggesting limited near-term upside. Investors should weigh growth prospects against valuation concerns and monitor Q3 2026 earnings for continued execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →
